Novus Therapeutics, Inc. announced the formation of a new Scientific Advisory Board (SAB), which is comprised of international experts in otolaryngology, pediatrics, and infectious diseases. The SAB will work closely with the Novus management team to advance OP0201, the company’s lead product candidate being developed for otitis media. Members of the Novus SAB include: Hamid Djalilian, M.D. Director of Otology, Neurotology, and Skull Base Surgery and a Professor of Otolaryngology and Biomedical Engineering at the University of California Irvine, California, USA. Paola Marchisio, M.D. Associate Professor of Pediatrics and Director of the Pediatric Unit at Fondazione IRCSS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy. Tal Marom, M.D. Associate Professor, Department of Otolaryngology-Head and Neck Surgery, Samson Assuta Ashdod University Hospital, Ben Gurion University Faculty of Health Sciences, Ashdod, Israel. Michael E. Pichichero, M.D. Director, Rochester General Hospital Research Institute, Rochester, New York, USA. Seth Pranksy, M.D. Pediatric Otolaryngology, Head and Neck Surgery, Rady Children’s Hospital San Diego, California, USA. Anne GM Schilder, M.D., Ph.D. Professor of Otolaryngology at University College London (UCL) Ear Institute, London, United Kingdom and University Medical Centre Utrecht (UMCU), Netherlands.